JPS5732225A - Human plasmatic crystalline alpha2-macroglobulin and its preparation - Google Patents

Human plasmatic crystalline alpha2-macroglobulin and its preparation

Info

Publication number
JPS5732225A
JPS5732225A JP10868180A JP10868180A JPS5732225A JP S5732225 A JPS5732225 A JP S5732225A JP 10868180 A JP10868180 A JP 10868180A JP 10868180 A JP10868180 A JP 10868180A JP S5732225 A JPS5732225 A JP S5732225A
Authority
JP
Japan
Prior art keywords
macroglobulin
human
crystalline
plasmatic
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10868180A
Other languages
Japanese (ja)
Inventor
Koichi Miyata
Shohei Nakamura
Katsumi Tomota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP10868180A priority Critical patent/JPS5732225A/en
Publication of JPS5732225A publication Critical patent/JPS5732225A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEW MATERIAL:A human plasmatic crystalline α2-macroglobulin. Molecular weight : 7.6×105 (measured by the gel filtration method with Sepharose 6B). Absorbance : E280 1%nm,1cm 8.3(25°C, 0.05M phosphoric acid buffer solution, pH7.0). Isoelectric point: pH5.3.
USE: A protease inhibitor, having improved storage stability because of the crystallinity, and capable of inhibiting the abnormal increase in protease activity due to the inflammation or pancreatitis of a living body and preventing the decomposition of peptide hormone or enzyme, etc. by the contaminant protease on purification by the addition thereto.
PROCESS: An α2-macroglobulin franction of a human plasma is concentrated by the ultrafiltration to give a human plasmatic crystalline α2-macroglobulin. The raw material α2-macroglobulin is obtained by separating and purifying a human dried plasma with the gel filtration and the colum chromatography.
COPYRIGHT: (C)1982,JPO&Japio
JP10868180A 1980-08-06 1980-08-06 Human plasmatic crystalline alpha2-macroglobulin and its preparation Pending JPS5732225A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10868180A JPS5732225A (en) 1980-08-06 1980-08-06 Human plasmatic crystalline alpha2-macroglobulin and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10868180A JPS5732225A (en) 1980-08-06 1980-08-06 Human plasmatic crystalline alpha2-macroglobulin and its preparation

Publications (1)

Publication Number Publication Date
JPS5732225A true JPS5732225A (en) 1982-02-20

Family

ID=14490964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10868180A Pending JPS5732225A (en) 1980-08-06 1980-08-06 Human plasmatic crystalline alpha2-macroglobulin and its preparation

Country Status (1)

Country Link
JP (1) JPS5732225A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2827882A4 (en) * 2012-02-21 2016-01-27 Cytonics Corp Systems, compositions, and methods for transplantation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2827882A4 (en) * 2012-02-21 2016-01-27 Cytonics Corp Systems, compositions, and methods for transplantation
AU2013222414B2 (en) * 2012-02-21 2018-02-15 Cytonics Corporation Systems, compositions, and methods for transplantation
US10265388B2 (en) 2012-02-21 2019-04-23 Cytonics Corporation Systems, compositions, and methods for transplantation
US10940189B2 (en) 2012-02-21 2021-03-09 Cytonics Corporation Systems, compositions, and methods for transplantation
US11040092B2 (en) 2012-02-21 2021-06-22 Cytonics Corporation Systems, compositions, and methods for transplantation

Similar Documents

Publication Publication Date Title
NO175716C (en) Analogous Process for Preparation of Therapeutically Active, Total and Partial Hyaluronic Acid Esters
JPS6434923A (en) Aerosolization of proteinaceous remedy
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
Zuber Purification and properties of a new carboxypeptidase from citrus fruit
PT87652A (en) PROCESS FOR THE PREPARATION OF PEPTIDE BOBONIC ACID INHIBITORS OF TRYPSIN-LIKE PROTEASES
NZ302984A (en) Multifunctional enzyme having N-terminal sequence IVGGXEVTPHAYPWQVGLFIDDMYF, where X is any amino acid
JPS6443152A (en) Stabilized chewing gum product and its production
CA1188218A (en) Purified antineoplaston fractions and methods of treating neoplastic disease
CA2053242C (en) Protease inhibitor
Janoff et al. Further studies on elastase-like esterases in human leukocyte granules
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
NZ510390A (en) TNF-alpha converting enzyme
FI871087A0 (en) Process for the preparation of therapeutically active 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo / oxo-5-pyrimidinecarboxylic acid derivatives
CA2105282A1 (en) Preparation of factor ix
Yamada et al. The effects of protease inhibitors on histidine decarboxylase activities and assay of enzyme in various rat tissues
AU5232886A (en) Serine protease inhibitors and methods for isolation of same
PL260757A1 (en) Procedure for the purification and production of /5r/ /z/-6-/1-methyl-1,2,3-triazole-4-ilomethylene/ penemo-3-carboxylic acid
JPS5732225A (en) Human plasmatic crystalline alpha2-macroglobulin and its preparation
EP0642348A4 (en) Antibiotic cryptdin peptides and methods of their use.
JPS6456699A (en) Method for obtaining alpha 1-antitrypsin concentrate from human plasma and its utilization as drug
AU4827085A (en) Method for treatment of antidiuresis employing serine derivatives
JPS649938A (en) Oral ingestive composition
NO164243C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE 16,17-ACETALS-SUBSTITUTED PREGNAN-21-ACETIC ACID DERIVATIVES
AU576750B2 (en) Method of determining antigenically active amino acid sequences
EP0261088A3 (en) Process for the production of heparanlysopeptide sulphate, the product thus obtained and its therapeutic use